Guardant Health Inc
GH105.420USD
+5.120+5.10%
Close 11/21, 16:00（ET）Quotes delayed by 15 min
13.18BMarket Cap
LossP/E TTM
More Details of Guardant Health Inc Company
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Guardant Health Inc Info
Ticker SymbolGH
Company nameGuardant Health Inc
IPO dateOct 04, 2018
CEODr. Amirali Talasaz, Ph.D.
Number of employees1999
Security typeOrdinary Share
Fiscal year-endOct 04
Address3100 Hanover Street
CityPALO ALTO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94304
Phone18556988887
Websitehttps://guardanthealth.com/
Ticker SymbolGH
IPO dateOct 04, 2018
CEODr. Amirali Talasaz, Ph.D.
Company Executives of Guardant Health Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Amirali Talasaz, Ph.D.
Dr. Amirali Talasaz, Ph.D.
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
2.52M
+0.47%
Dr. Helmy A. Eltoukhy, Ph.D.
Dr. Helmy A. Eltoukhy, Ph.D.
Chairperson of the Board, Co-Chief Executive Officer
Chairperson of the Board, Co-Chief Executive Officer
2.47M
+0.48%
Dr. Darya Chudova
Dr. Darya Chudova
Chief Technology Officer
Chief Technology Officer
88.53K
+9.85%
Dr. Craig Eagle, M.D.
Dr. Craig Eagle, M.D.
Chief Medical Officer
Chief Medical Officer
44.32K
+18.23%
Mr. John Gomes Saia
Mr. John Gomes Saia
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
43.17K
-17.24%
Ms. Vijaya V. Gadde
Ms. Vijaya V. Gadde
Independent Director
Independent Director
24.31K
+37.83%
Mr. Kumud Kalia
Mr. Kumud Kalia
Chief Information Officer
Chief Information Officer
21.68K
+31.56%
Ms. Myrtle Stephens Potter
Ms. Myrtle Stephens Potter
Independent Director
Independent Director
18.32K
+0.24%
Ms. Meghan V. Joyce
Ms. Meghan V. Joyce
Independent Director
Independent Director
11.18K
-0.89%
Mr. Musa Tariq
Mr. Musa Tariq
Independent Director
Independent Director
7.86K
+1.73%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Amirali Talasaz, Ph.D.
Dr. Amirali Talasaz, Ph.D.
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
2.52M
+0.47%
Dr. Helmy A. Eltoukhy, Ph.D.
Dr. Helmy A. Eltoukhy, Ph.D.
Chairperson of the Board, Co-Chief Executive Officer
Chairperson of the Board, Co-Chief Executive Officer
2.47M
+0.48%
Dr. Darya Chudova
Dr. Darya Chudova
Chief Technology Officer
Chief Technology Officer
88.53K
+9.85%
Dr. Craig Eagle, M.D.
Dr. Craig Eagle, M.D.
Chief Medical Officer
Chief Medical Officer
44.32K
+18.23%
Mr. John Gomes Saia
Mr. John Gomes Saia
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
43.17K
-17.24%
Ms. Vijaya V. Gadde
Ms. Vijaya V. Gadde
Independent Director
Independent Director
24.31K
+37.83%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Oncology
158.69M
68.37%
Biopharma and data
56.02M
24.14%
Screening
14.81M
6.38%
Licensing and other
2.57M
1.11%
By RegionUSD
Name
Revenue
Proportion
United States
216.68M
93.36%
International
15.40M
6.64%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Oncology
158.69M
68.37%
Biopharma and data
56.02M
24.14%
Screening
14.81M
6.38%
Licensing and other
2.57M
1.11%
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.22%
BlackRock Institutional Trust Company, N.A.
6.65%
Baillie Gifford & Co.
3.98%
Capital International Investors
3.64%
Invesco Advisers, Inc.
3.60%
Other
72.90%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.22%
BlackRock Institutional Trust Company, N.A.
6.65%
Baillie Gifford & Co.
3.98%
Capital International Investors
3.64%
Invesco Advisers, Inc.
3.60%
Other
72.90%
Shareholder Types
Shareholders
Proportion
Investment Advisor
46.03%
Investment Advisor/Hedge Fund
30.38%
Hedge Fund
14.68%
Individual Investor
4.22%
Sovereign Wealth Fund
1.77%
Research Firm
1.76%
Bank and Trust
1.57%
Pension Fund
0.81%
Family Office
0.05%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
765
128.93M
100.07%
-13.82M
2025Q2
759
134.16M
107.59%
-14.14M
2025Q1
783
130.34M
105.23%
-16.59M
2024Q4
746
130.16M
105.47%
-20.09M
2024Q3
780
137.29M
111.53%
-9.70M
2024Q2
801
127.50M
103.74%
-18.45M
2024Q1
826
124.00M
101.88%
-12.71M
2023Q4
856
120.18M
99.30%
-14.26M
2023Q3
867
117.78M
100.31%
-19.15M
2023Q2
890
119.83M
102.55%
+840.96K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
12.14M
9.74%
+89.50K
+0.74%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.39M
6.73%
-215.41K
-2.50%
Jun 30, 2025
Baillie Gifford & Co.
4.81M
3.86%
-251.22K
-4.96%
Jun 30, 2025
Capital International Investors
4.98M
3.99%
-171.27K
-3.33%
Jun 30, 2025
Invesco Advisers, Inc.
3.40M
2.73%
+789.69K
+30.20%
Jun 30, 2025
Deep Track Capital LP
4.25M
3.41%
-1.19M
-21.93%
Jun 30, 2025
Two Sigma Investments, LP
4.24M
3.4%
+42.75K
+1.02%
Jun 30, 2025
Eventide Asset Management, LLC
3.46M
2.77%
-107.78K
-3.02%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Franklin Genomic Advancements ETF
5.23%
Global X Genomics & Biotechnology ETF
4.87%
ARK Genomic Revolution ETF
4.37%
First Trust Nasdaq Lux Digi Health Solutions ETF
3.46%
Invesco Dorsey Wright Healthcare Momentum ETF
3.44%
SPDR S&P Health Care Services ETF
2.1%
ROBO Global Healthcare Technology & Innovation ETF
2.07%
iShares Health Innovation Active ETF
1.76%
Alger Mid Cap 40 ETF
1.67%
Simplify Health Care ETF
1.49%
View more
Franklin Genomic Advancements ETF
Proportion5.23%
Global X Genomics & Biotechnology ETF
Proportion4.87%
ARK Genomic Revolution ETF
Proportion4.37%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion3.46%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion3.44%
SPDR S&P Health Care Services ETF
Proportion2.1%
ROBO Global Healthcare Technology & Innovation ETF
Proportion2.07%
iShares Health Innovation Active ETF
Proportion1.76%
Alger Mid Cap 40 ETF
Proportion1.67%
Simplify Health Care ETF
Proportion1.49%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Guardant Health Inc?
The top five shareholders of Guardant Health Inc are:
The Vanguard Group, Inc. holds 12.14M shares, accounting for 9.74% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.39M shares, accounting for 6.73% of the total shares.
Baillie Gifford & Co. holds 4.81M shares, accounting for 3.86% of the total shares.
Capital International Investors holds 4.98M shares, accounting for 3.99% of the total shares.
Invesco Advisers, Inc. holds 3.40M shares, accounting for 2.73% of the total shares.
The Vanguard Group, Inc. holds 12.14M shares, accounting for 9.74% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.39M shares, accounting for 6.73% of the total shares.
Baillie Gifford & Co. holds 4.81M shares, accounting for 3.86% of the total shares.
Capital International Investors holds 4.98M shares, accounting for 3.99% of the total shares.
Invesco Advisers, Inc. holds 3.40M shares, accounting for 2.73% of the total shares.
What are the top three shareholder types of Guardant Health Inc?
The top three shareholder types of Guardant Health Inc are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Baillie Gifford & Co.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Baillie Gifford & Co.
How many institutions hold shares of Guardant Health Inc (GH)?
As of 2025Q3, 765 institutions hold shares of Guardant Health Inc, with a combined market value of approximately 128.93M, accounting for 100.07% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -7.52%.
What is the biggest source of revenue for Guardant Health Inc?
In FY2025Q2, the Oncology business generated the highest revenue for Guardant Health Inc, amounting to 158.69M and accounting for 68.37% of total revenue.
